160 related articles for article (PubMed ID: 26931461)
1. Cathepsin K induces platelet dysfunction and affects cell signaling in breast cancer - molecularly distinct behavior of cathepsin K in breast cancer.
Andrade SS; Gouvea IE; Silva MC; Castro ED; de Paula CA; Okamoto D; Oliveira L; Peres GB; Ottaiano T; Facina G; Nazário AC; Campos AH; Paredes-Gamero EJ; Juliano M; da Silva ID; Oliva ML; Girão MJ
BMC Cancer; 2016 Mar; 16():173. PubMed ID: 26931461
[TBL] [Abstract][Full Text] [Related]
2. Lysosomal protein turnover contributes to the acquisition of TGFβ-1 induced invasive properties of mammary cancer cells.
Kern U; Wischnewski V; Biniossek ML; Schilling O; Reinheckel T
Mol Cancer; 2015 Feb; 14():39. PubMed ID: 25744631
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil proteases can inactivate human PAR3 and abolish the co-receptor function of PAR3 on murine platelets.
Cumashi A; Ansuini H; Celli N; De Blasi A; O'Brien PJ; Brass LF; Molino M
Thromb Haemost; 2001 Mar; 85(3):533-8. PubMed ID: 11307827
[TBL] [Abstract][Full Text] [Related]
4. Cathepsin G activates protease-activated receptor-4 in human platelets.
Sambrano GR; Huang W; Faruqi T; Mahrus S; Craik C; Coughlin SR
J Biol Chem; 2000 Mar; 275(10):6819-23. PubMed ID: 10702240
[TBL] [Abstract][Full Text] [Related]
5. The mechanism of anti-platelet activity of davallialactone: involvement of intracellular calcium ions, extracellular signal-regulated kinase 2 and p38 mitogen-activated protein kinase.
Kim SD; Lee IK; Lee WM; Cho JY; Park HJ; Oh JW; Park SC; Kim SK; Kwak YS; Yun BS; Rhee MH
Eur J Pharmacol; 2008 Apr; 584(2-3):361-7. PubMed ID: 18313047
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of Integrins in Cancer Cells and Anti-Platelet Properties Are Involved in Holothurian Glycosaminoglycan-Mediated Disruption of the Interaction of Cancer Cells and Platelets in Hematogenous Metastasis.
Qian W; Tao L; Wang Y; Zhang F; Li M; Huang S; Wang A; Chen W; Yue Z; Chen L; Liu Y; Huang C; Zhang L; Li Y; Lu Y
J Vasc Res; 2015; 52(3):197-209. PubMed ID: 26488158
[TBL] [Abstract][Full Text] [Related]
7. Induction of central signalling pathways and select functional effects in human platelets by beta-boswellic acid.
Poeckel D; Tausch L; Altmann A; Feisst C; Klinkhardt U; Graff J; Harder S; Werz O
Br J Pharmacol; 2005 Oct; 146(4):514-24. PubMed ID: 16086030
[TBL] [Abstract][Full Text] [Related]
8. Cathepsin G and thrombin: evidence for two different platelet receptors.
Selak MA
Biochem J; 1994 Jan; 297 ( Pt 2)(Pt 2):269-75. PubMed ID: 8297330
[TBL] [Abstract][Full Text] [Related]
9. Thrombin- and cathepsin G-induced platelet aggregation: effect of protein kinase C inhibitors.
Puri RN; Colman RW
Anal Biochem; 1993 Apr; 210(1):50-7. PubMed ID: 7683848
[TBL] [Abstract][Full Text] [Related]
10. TCDD and omeprazole prime platelets through the aryl hydrocarbon receptor (AhR) non-genomic pathway.
Pombo M; Lamé MW; Walker NJ; Huynh DH; Tablin F
Toxicol Lett; 2015 May; 235(1):28-36. PubMed ID: 25797602
[TBL] [Abstract][Full Text] [Related]
11. Regulation of protease-activated receptor (PAR) 1 and PAR4 signaling in human platelets by compartmentalized cyclic nucleotide actions.
Bilodeau ML; Hamm HE
J Pharmacol Exp Ther; 2007 Aug; 322(2):778-88. PubMed ID: 17525299
[TBL] [Abstract][Full Text] [Related]
12. The toll-like receptor 2/1 (TLR2/1) complex initiates human platelet activation via the src/Syk/LAT/PLCγ2 signalling cascade.
Fälker K; Klarström-Engström K; Bengtsson T; Lindahl TL; Grenegård M
Cell Signal; 2014 Feb; 26(2):279-86. PubMed ID: 24240055
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of PAR1 antagonists, PAR4 antagonists, and their combinations on thrombin-induced human platelet activation.
Wu CC; Teng CM
Eur J Pharmacol; 2006 Sep; 546(1-3):142-7. PubMed ID: 16890935
[TBL] [Abstract][Full Text] [Related]
14. The focal adhesion kinase Pyk2 links Ca2+ signalling to Src family kinase activation and protein tyrosine phosphorylation in thrombin-stimulated platelets.
Canobbio I; Cipolla L; Guidetti GF; Manganaro D; Visconte C; Kim S; Okigaki M; Falasca M; Kunapuli SP; Torti M
Biochem J; 2015 Jul; 469(2):199-210. PubMed ID: 25967238
[TBL] [Abstract][Full Text] [Related]
15. Difference of (Ca2+)i movements in platelets stimulated by thrombin and TRAP: the involvement of alpha(IIb)beta3-mediated TXA2 synthesis.
Aoki T; Tomiyama Y; Honda S; Senzaki K; Tanaka A; Okubo M; Takahashi F; Takasugi H; Seki J
Thromb Haemost; 1998 Jun; 79(6):1184-90. PubMed ID: 9657446
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3.
Wu CC; Hwang TL; Liao CH; Kuo SC; Lee FY; Lee CY; Teng CM
Thromb Haemost; 2002 Jun; 87(6):1026-33. PubMed ID: 12083482
[TBL] [Abstract][Full Text] [Related]
17. Levobupivacaine differentially suppresses platelet aggregation by modulating calcium release in a dose-dependent manner.
Liou JT; Mao CC; Liu FC; Lin HT; Hung LM; Liao CH; Day YJ
Acta Anaesthesiol Taiwan; 2012 Sep; 50(3):112-21. PubMed ID: 23026170
[TBL] [Abstract][Full Text] [Related]
18. Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin.
Vega-Ostertag M; Harris EN; Pierangeli SS
Arthritis Rheum; 2004 Sep; 50(9):2911-9. PubMed ID: 15457460
[TBL] [Abstract][Full Text] [Related]
19. Amyloid beta peptide-activated signal pathways in human platelets.
Shen MY; Hsiao G; Fong TH; Chen HM; Chou DS; Lin CH; Sheu JR; Hsu CY
Eur J Pharmacol; 2008 Jul; 588(2-3):259-66. PubMed ID: 18511035
[TBL] [Abstract][Full Text] [Related]
20. Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation.
Kuliopulos A; Mohanlal R; Covic L
Thromb Haemost; 2004 Dec; 92(6):1387-93. PubMed ID: 15583748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
